Phase I Trial of Weekly Gemcitabine and Concurrent Radiotherapy in Patients With Inoperable Non-Small-Cell Lung Cancer

Abstract
PURPOSE: To report the evidence of a phase I trial planned to determine the maximum-tolerated dose (MTD) and related toxicity of weekly gemcitabine (GEM) and concurrent radiotherapy in patients with non–small-cell lung cancer (NSCLC). In addition, the response to treatment was evaluated and reported.

This publication has 0 references indexed in Scilit: